Skip to main content

. 1989 Jun 10;298(6687):1560–1561. doi: 10.1136/bmj.298.6687.1560

Hypophosphataemic rickets after ifosfamide treatment in children.

R Skinner ¹, A D Pearson ¹, L Price ¹, K Cunningham ¹, A W Craft ¹

PMCID: PMC1836803 PMID: 2503116

1560

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

DeFronzo R. A., Abeloff M., Braine H., Humphrey R. L., Davis P. J. Renal dysfunction after treatment with isophosphamide (NSC-109724). Cancer Chemother Rep. 1974 May-Jun;58(3):375–382. [PubMed] [Google Scholar]
Pinkerton C. R., Rogers H., James C., Bowman A., Barbor P. R., Eden O. B., Pritchard J. A phase II study of ifosfamide in children with recurrent solid tumours. Cancer Chemother Pharmacol. 1985;15(3):258–262. doi: 10.1007/BF00263897. [DOI] [PubMed] [Google Scholar]
Sangster G., Kaye S. B., Calman K. C., Dalton J. F. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol. 1984 Mar;20(3):435–436. doi: 10.1016/0277-5379(84)90093-2. [DOI] [PubMed] [Google Scholar]
Van Dyk J. J., Falkson H. C., Van der Merwe A. M., Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Res. 1972 May;32(5):921–924. [PubMed] [Google Scholar]

ACTIONS

RESOURCES